Press Releases

  • Mar. 14, 2012 biOasis’ BT2111-Herceptin? Program Achieves Significant Positive Results From Antibody Dependent Cell-Mediated Cytotoxicity Assay

    Vancouver, B.C.–(Business Wire)– biOasis Technologies Inc. (TSX:V.BTI) today announces positive test results from its Transcend therapeutic BT2111 development program directed towards the delivery of the therapeutic monoclonal antibody Herceptin? to the brain. An ADCC (antibody dependent cell-mediated cytotoxicity) assay showed that BT2111 conjugates retained Fc receptor binding activity and mediated human immune cell killing of… Read more »

  • Feb. 16, 2012 biOasis named to TSX Venture 50®

    Vancouver, B.C.–(Business Wire)– biOasis Technologies Inc. (TSX:V.BTI) announces it has been named one of the 2012 TSX Venture 50® companies. The TSX Venture 50® includes the top 10 companies in 5 major industry sectors that have been identified as leaders in providing shareholder value on Canada’s junior stock exchange. “We are very proud to be… Read more »

  • Jan. 31, 2012 biOasis Advances its Herceptin® BT2111 Program

    Vancouver, B.C.–(Business Wire)– biOasis Technologies Inc. (TSX:V.BTI) announced today that work is underway at Texas Tech University Health Sciences Center (TTUHSC) to perform a series of preclinical studies designed to evaluate the pharmacokinetics of BT2111 (a proprietary conjugate of p97 and Herceptin®) in animal models of breast cancer metastasis in the brain. The studies at… Read more »

  • Jan. 17, 2012 biOasis Enters Investor Relations Agreement with Brisco Capital Partners Corp.

    Vancouver, B.C.–(Business Wire)– biOasis Technologies Inc. (TSX.V: BTI) (the “Company”) is pleased to announce that it has Brisco Capital Partners Corp. (“Brisco”) to provide investor relations, subject to regulatory approval. Brisco will initiate and maintain contact with the financial community, shareholders, investors and other stakeholders for the purpose of increasing awareness of the Company and… Read more »

  • Nov. 30, 2011 biOasis Announces Closing of Private Placement

    Vancouver, BC–(Business Wire)– biOasis Technologies Inc. (TSX.V:BTI) is pleased to announce a non-brokered private placement of up to 2,250,000 units at a price of $0.45 per unit for gross proceeds of up to $1,012,500 with an overallotment of up to 20%. Each unit will consist of one common share and one full common share purchase… Read more »

  • Nov. 25, 2011 biOasis announces Non-Brokered Private Placement

    Vancouver, BC–(Business Wire)– biOasis Technologies Inc. (TSX.V:BTI) is pleased to announce a non-brokered private placement of up to 2,250,000 units at a price of $0.45 per unit for gross proceeds of up to $1,012,500 with an overallotment of up to 20%. Each unit will consist of one common share and one full common share purchase… Read more »

  • Nov. 24, 2011 biOasis Enters Research, Evaluation and Option Agreement with Shire Human Genetic Therapies, Inc.

    Vancouver, BC–(Business Wire)– biOasis Technologies Inc. (TSX.V:BTI) announced today that it has entered into a research, evaluation and option agreement with Shire Human Genetic Therapies, Inc. (Shire) to evaluate biOasis’s Transcend technology in the area of lysosomal storage disorders (LSDs). In connection with this agreement, biOasis and Shire are undertaking certain experiments at their own… Read more »

  • Nov. 1, 2011 biOasis Transcend Vector Delivers an Anti-Amyloid Beta (A?) Antibody To The Brain

    Vancouver, BC–(Business Wire)– biOasis Technologies Inc. (TSX.V:BTI) today announced test results from its Transcend therapeutic development program directed towards the delivery of targeted therapeutic compounds to the brain which showed that Transcend can deliver an anti-amyloid beta antibody to the brain. The work was conducted on behalf of the Company by the National Research Council… Read more »

  • Oct. 17, 2011 biOasis Receives Final Results from BC Cancer Research Centre Herceptin® Studies

    Vancouver, BC–(Business Wire)– biOasis Technologies Inc. (TSX.V:BTI) announced today the results from two additional studies conducted by the BC Cancer Research Centre (BCCRC). The additional studies confirmed and extended earlier data showing that BT2111, a conjugate made up of biOasis Transcend vector and trastuzumab (trade name Herceptin®), a humanized monoclonal antibody used clinically in the… Read more »

  • Sep. 2, 2011 Option Grant – biOasis Technologies Inc.

    Vancouver, BC–(Business Wire)– biOasis Technologies Inc. (TSX.V:BTI) announces that it has granted options to its officers, employees, consultants and members of the board of directors. A total of 2,275,000 options have been granted effective at the close of business on September 1st, 2011. The options are exercisable at a price of $0.52 per share until… Read more »